Mr. Sullivan brings to Convergent over 20 years of finance and operations experience in the biotechnology industry working on financial management, strategic planning, and fundraising and capital market transactions across the public and private markets. Prior to joining Convergent, he was Chief Financial Officer at TCR² Therapeutics through the completion of the acquisition by Adaptimmune Therapeutics. Before that he was President and Chief Financial Officer at Triplet Therapeutics where he led finance, business development and corporate operations. Earlier in his career he held senior management positions at Gemini Therapeutics, Oncorus, bluebird bio, Merrimack Pharmaceuticals and PwC. Mr. Sullivan holds a B.S. in Accountancy from Bentley University and is a Certified Public Accountant.